Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Consensus Target Price of $36.25

Nuvectis Pharma, Inc. (NASDAQ:NVCT) has received a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $36.25.

NVCT has been the topic of a number of recent research reports. Loop Capital set a $40.00 price objective on Nuvectis Pharma in a research note on Tuesday, September 1st. Weiss Ratings raised Nuvectis Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 21st. HC Wainwright restated a “buy” rating and issued a $39.00 price target on shares of Nuvectis Pharma in a research report on Thursday, September 24th. Lucid Cap Mkts upgraded Nuvectis Pharma to a “strong-buy” rating in a research note on Tuesday, September 1st. Finally, Cantor Fitzgerald started coverage on shares of Nuvectis Pharma in a research note on Monday, August 24th. They issued an “overweight” rating for the company.

Institutional Trading of Nuvectis Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Iridian Asset Management LLC CT grew its holdings in shares of Nuvectis Pharma by 2.1% during the 3rd quarter. Iridian Asset Management LLC CT now owns 793,207 shares of the company’s stock worth $16,753,000 after acquiring an additional 16,129 shares during the period. Alyeska Investment Group L.P. purchased a new stake in Nuvectis Pharma in the second quarter worth $5,057,000. Stonepine Capital Management LLC bought a new stake in Nuvectis Pharma during the 2nd quarter valued at $735,600. Bank of America Corp DE acquired a new position in Nuvectis Pharma during the 2nd quarter valued at approximately $218,000. Finally, Legal & General Group Plc acquired a new stake in shares of Nuvectis Pharma during the 2nd quarter worth approximately $31,000. Institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Price Performance

NVCT stock opened at $20.05 on Friday. The company has a 50-day moving average of $21.82 and a two-hundred day moving average of $16.92. Nuvectis Pharma has a 52-week low of $5.55 and a 52-week high of $29.27. The stock has a market capitalization of $654.43 million, a price-to-earnings ratio of -15.31 and a beta of -0.24.

Nuvectis Pharma (NASDAQ:NVCT) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Equities analysts expect that Nuvectis Pharma will post -1.01 EPS for the current fiscal year.

About Nuvectis Pharma

Nuvectis Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, with an emphasis on cancers that have limited therapeutic options. The company is headquartered in Fort Lee, New Jersey, and its common stock trades on the Nasdaq Capital Market under the symbol NVCT.

Nuvectis Pharma’s lead product candidate is NXP800, an orally administered small-molecule inhibitor of heat shock protein 90 (HSP90). The company is evaluating NXP800 in clinical studies for certain advanced solid tumors, including platinum-resistant ovarian cancer and cholangiocarcinoma.